High CIP2A-expressing patients have inferior survival from relapse. (A) Diagnostic CIP2A protein level in 120 AML patients. AML15 are younger patients; AML16 are older patients. AML15 normal karyotype (N = 39); AML15 adverse karyotype (n = 40); and AML16 normal karyotype (N = 41). (B) AML15 normal karyotype patients stratified by diagnostic CIP2A level. P values are only significant where shown. Survival from relapse. The numbers of assessable cases are shown below each plot. The log-rank test was used for Kaplan-Meier estimates. (C) CIP2A level stratified by FLT3-ITD mutation status. *Denotes statistical significance when compared to normal MNC cells.